T-cell receptor (TCR) recognizing MHC-presented Spike protein antigen (TCR (when context is clear, referring to antigen-specific TCR))

The T-cell receptor (TCR) is a heterodimeric transmembrane protein found on the surface of T cells, responsible for recognizing antigenic peptides that are bound to major histocompatibility complex (MHC) molecules on other cells. When the antigen is derived from the SARS-CoV-2 Spike protein, the complex is referred to as a Spike-specific TCR engaging MHC-presented Spike peptide. TCR specificity is determined by its α and β chains, which collectively recognize the unique peptide-MHC complex (pMHC)[2][3][4]. This recognition event is the key initial step for T cell activation, leading to an adaptive immune response. The overall diversity of the TCR repertoire enables broad recognition of a variety of pathogens and tumor antigens. In the context of COVID-19, TCRs that bind to Spike-derived peptides presented by MHC are critical for viral clearance and are an active research and therapeutic target, including in vaccine design and T cell-based immunotherapies[7]. There is ongoing debate on whether the Spike protein can act as a superantigen; however, recent high-quality experimental evidence argues against the Spike protein acting directly as a TCR superantigen[5][6]. Notes on Naming and Correctness: The query’s target name "T-cell receptor via MHC-presented Spike antigen" describes a functional interaction, not a unique protein. The correct entity is *the T-cell receptor (TCR) specific for Spike-derived peptides presented by MHC*—typically named "Spike protein-specific T-cell receptor" or "SARS-CoV-2 Spike-specific TCR." For structured databases, these entries should be separated: TCR (the receptor) and its peptide-MHC ligand (the presented Spike peptide on MHC)[2][3][4]. The submitted target name is therefore too broad and imprecise; it is not standard.

Other names

TCR specific for Spike antigenSARS-CoV-2 Spike-specific T-cell receptorAntigen-specific T-cell receptorPeptide-MHC-specific TCR

Recognition and binding of a specific antigenic peptide presented by MHC molecules on host cells, leading to T cell activation, cytokine release, and possibly targeted cell killing[2][3][4]. Drug targeting involves modulating this recognition, either augmenting (e.g., cancer therapy) or suppressing (e.g., autoimmunity/transplantation) T cell response.